We have performed a comparative evaluation of two Immuno Radiometrie Assay (IRMA) kits for parathyrin against an existing Radioimmuno Assay (RIA) technique for the measurement of intact parathyrin.
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The development of IRMA techniques has revolutionised other fields of endocrine hormone assay where there has been a need for improved detection limits and imprecision for the clinical application. It was predicted that a similar benefit would accrue by application of these techniques to the assay of intact parathyrin. A number of commercial kits have been developed in an attempt to achieve this. Here we describe an analytical assessment of two of the more popular IRMA kits for intact parathyrin against our current routine parathyrin assay.
Materials and Methods

Analytical evaluation
The analytical assessment consisted of comparing two IRMA kits (Kit A and B) for whole molecule parathyrin with an established RIA whole molecule parathyrin kit (Kit C) currently in routine use. Following incubation, the bead is washed to remove unbound components and the radioactivity bound to the solid phase is measured in a gamma counter. The radioactivity of the bead bound complex is directly proportional to the amount of intact parathyrin in the sample.
Kit C
Human Ntact® parathyrin by RIA product no. 69065 (Incstar Corporation, Stillwater, Minnesota). This measures intact parathyrin utilising extraction followed by conventional radioimmunoassay technique. Extraction and concentration of intact parathyrin in plasma is achieved using specific absorption particles which remove only intact parathyrin and N terminal fragments. Following elution of parathyrin from these particles, assay by RIA is performed.
Following a period of familiarisation with the kits, evaluation was carried out as detailed adhering where appropriate to the ECCLS guidelines (4).
An established sample data base was already in existence within the laboratory, consisting of samples collected and stored under optimum conditions.
Statistical evaluation
The assay limit of detection was defined as the concentration corresponding to the 95% confidence limits of counts obtained for replicates of zero standards assayed in a single batch.
Regression and correlation studies were carried out using standard Deming regression equations. The straight line model correlation coefficient was used based on the Deming plots.
Results
Imprecision
Ten replicates of pooled human serum were analyzed in a single batch to assess within batch imprecision. Overall (between-batch) imprecision was assessed using the same serum pool assayed in duplicate in each of 11 assays. The results of within batch and overall imprecision are shown in table 1. For an equivalent number of assays, the Ntact RIA kit showed an overall CV of 14.2% at a mean concentration of 74 ng/1.
Assay limit of detection
Twenty replicate analyses of a zero standard were made and the limit of detection defined as given in the method section. The limit of detection was shown to 2.36 ng/1 for the Ntact IRMA kit and 3.71 ng/1 for the Allegro kit. The Ntact RIA kit has a limit of detection of 28 ng/1 based on the same algorithm.
Dose response and parallelism
Using a range of dilutions of the International Reference Preparation for parathyrin (IRP 79/500) obtained from the National Institute for Biological Standards and Control, linearity was assessed over the concentration range 31.25 to 10000 ng/1 ( fig. 1 ). All dilutions of the IRP were prepared in phosphate buffered saline (pH 7.4) containing 300 g/1 albumin.
Parallelism was investigated using 2 human plasma samples known to contain elevated concentrations of parathyrin. Varying dilutions of these were made in the kit zero standard. The concentrations obtained were corrected for the dilution factor and expressed as a percentage of the concentration measured in the undiluted sample (tab. 2). 
Specimen requirements
Since parathyrin is a labile molecule, specimen collection and storage are of the utmost importance. Blood samples from 4 patients were collected into plain glass bottles for serum harvest and into bottles containing potassium-EDTA as preservative for plasma harvest. These samples underwent varying treatment with regard to separation and storage. All sample from an individual patient were analyzed in a single batch to obtain the results given in table 4. A difference in concentration from samples separated within 30 minutes at + 4 °C and stored at -20 °C of greater than (2 χ SD analytica i) was taken as significant change.
Other factors
Laboratory staff involved in the evaluation were asked to record their subjective opinions of each kit with regard to packaging, instructions, ease of use etc. The cost per patient sample was also calculated.
Discussion
The contribution of parathyrin assay to the differential diagnosis of patients with hypercalcaemia has been contentious since its estimation was established.
A number of factors appear to contribute to the various claims, amongst which are the parathyrin moiety used as a measure of circulating parathyrin status and the performance characteristics on the technique chosen to measure this.
Most commercial endeavour has been invested in improving the assay of whole molecule parathyrin. The two commercial kits evaluated here have been developed utilising IRMA technology (5, 6) , and the manufacturers claim significant improvement in the analytical and clinical diagnostic utility in hypercalcaemic patients.
Minor improvements in overall imprecision were noted for both IRMA kits compared with the current radioimmunoassay at equivalent concentrations, which may reflect the avoidance of an extraction procedure.
The limit of detection for both IRMA kits showed approximately a 10 fold improvement over the conventional technique and should therefore permit identification of patients with suppressed levels of parathyrin. This improvement was not reflected by a greater improvement in assay precision but it is possible that had we assessed RIA precision at a parathyrin concentration closer to that used in the IRMA kit quality assurance material the difference might have been more marked.
Although standards provided in the kits only range from 0-2000 ng/1 (Incstar Ntact) or 0-1650 ng/1 (Nichols Allegro), the theoretical working range of the assays is approximately 5 times this concentration range. A standard curve prepared from IRP 79/500, showed acceptable linearity with no evidence of a high dose hook effect up to 10000 ng/1. It is interesting that a similar discrepancy was shown in the accuracy study utilising the IRP. Neither kit quotes the basis of their standardisation and whilst the Allegro kit underestimated the concentration across the whole standard range, the Ntact kit appeared to overestimate at lower concentrations and underestimate at higher concentrations.
Both IRMA kits were shown to be acceptable for use outwith their quoted expiry dates which is advantageous if regular useage is not envisaged.
Deming analysis showed good correlation between the concentrations measured by the IRMA kits when compared with the existing whole molecule assay.
One major point highlighted in this technical evaluation was that of improved sample stability over that seen in the RIA assay routinely. The existing requirement has been for plasma samples collected, separated and frozen within 30 minutes. After this period a marked decline in the concentration of intact parathyrin measured had been noted (7).
Utilising the IRMA kits however, a less rigid requirement was demonstrated. Standing for up to 2 hours at room temperature appeared to have little effect on the measured dose, providing that samples were then stored frozen. Plasma samples seemed less sensitive to storage conditions than serum samples. This is in contrast to the findings of Newman & Ashby (8) .
Subjective impressions of both IRMA kits were favourable compared to the RIA method which involves an extraction procedure. In terms of hands on time however, all three assays were comparable. The IRMA kits were less expensive per patient sample than the RIA kit although the assay turn round time is longer for the IRMA kit. In a practical situation however this fact is irrelevant.
As neither of the IRMA kits under assessment showed significant technical superiority over the other, the decision of which kit to use rests soley on the performance in the clinical setting. The clinical assessment is proceeding at present and will be reported on when completed.
